ANAGENICS LIMITED (AN1)

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company reported a net loss of $0.5m for the half-year ended 31 December 2024, a significant improvement from the previous year. The business restructure improved net operating cash flow, with an outflow of $0.3m in 2Q25. The company completed a transition to in-house solutions and new ERP systems, resulting in growth in sales.

The company will hold its general meeting on 3 April 2025, 10:00am (Sydney time) at Suite 204, Level 2, 55 Clarence Street Sydney NSW 2000.

The company releases its appendix 4D and half year report.

The company reported a total payment of $65k to related parties and associates for the 2Q25 Qtrly Activity Report, including wages, fees, and GST paid to former directors.

The company reports Roquefort Therapeutics has signed a binding share purchase agreement for the sale of Lyramid to Pleiades Pharma, following a previous term sheet with Pleiades.

The company lodges its Activity Statement and Appendix 4C.

The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day.

The company receives additional information from the ASX for relisting its securities, including lodgement of quarterly activities report, audit reviewed financial position, sufficient operations, and issuing shares.

The company has received an update on Roquefort Therapeutics' announcement of a proposed sale of its midkine portfolio, including royalties from products using its intellectual property. The company is making further inquiries and is pursuing discussions with the ASX to end the suspension in trading.

The company has completed its restructuring program, aiming to return the company to profitability. The restructure includes in-housing third-party logistics and exiting the Chinese online sales channel. Total cost reductions are expected to exceed $2.5 million annually. Anagenics now has a clear strategy focused on profitability, strengthening royalty revenue streams, new brand releases, and pursuing accretive acquisitions.

The company releases the results of its annual general meeting.

The company lodges its 2024 AGM Presentation.

The company lodges its Q1 F25 Activity Statement and Appendix 4C.

The company is undergoing a restructuring program to reposition itself with a simplified business model, aiming for modest profitability. The company has disposed of a loss-making business and reduced liabilities. The restructuring includes reducing head count, replacing IT and ERP systems, and reducing overhead costs.

The company 2024 Annual General Meeting is scheduled for November 26, 2024, at Level 2, 55 Clarence Street Sydney NSW 2000, at 9.00 am (AEDT).

The company has completed the sale of Face MediGroup, as previously announced on October 2, 2024.

The company will release 13,157,895 fully paid ordinary shares from escrow on 11 October 2024, following a 12-month voluntary escrow period, as per ASX Listing Rule 3.10A.

The company's Board announces a restructuring update, focusing on business simplification and cost reduction. The company's exit from Face MediGroup and the removal of legacy expenses are part of a plan to achieve modest profitability.

The company releases its Appendix 4G and Corporate Governance Statement.

The Company has entered into an agreement for the sale of its Face MediGroup business to the co-founders of the business, Matthew Perry and Sarah Jane Perry, and their entities controlled by them. The transaction will see the Company fully exit the FMG business, with the purchasers taking on all assets, liabilities and business specific employees with their accrued entitlements, allowing the Company to reduce its operating costs and avoid significant further costs. The consideration comprises the assumption of FMG's liabilities and cancellation of the Company's obligation to pay approximately $670,000 to the co-founders by way of deferred consideration and loan repayment, supported by mutual releases given by each party. No cash consideration will be exchanged on settlement of this transaction. Completion of the transaction is expected to occur on 15 October 2024.

The company lodges its Annual Report to shareholders.

The Company is actively engaged with a number of third parties in relation to multiple restructuring workstreams for the business, including management and funding strategies for the ongoing business. Successful completion of the Restructuring is critical to the Company's continued financial sustainability. Discussions with third parties are progressing positively and constructively. In the Company's opinion, trading of its securities during this time is likely to materially prejudice its ability to complete the discussions with third parties. The Company's suspension will remain in place until the Company releases a further announcement regarding the Restructuring. Discussions are ongoing and it is difficult to predict a timetable for their conclusion. However, the Company is working towards finalising these matters as soon as practicable and is aiming to do so by Monday, 30 September 2024.

The securities of Anagenics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AN1, pending the release of an announcement regarding its proposed restructure and financing to fund the ongoing operations which are critical to its continued financial viability.

name changed from Cellmid Limited